| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2023 | AURORA ONCOLOGY, INC. | 12635 E MONTVIEW BLVD | AURORA | CO | 80045-7335 | ADAMS | USA | R44CA232963 | DT-EGF Toxic Fusion Protein for the Treatment of Bladder Cancer | 000 | 3 | NIH | 7/8/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $999,955 ) |
| | 2023 | 2023 | AURORA ONCOLOGY INC | 12635 E MONTVIEW BLVD | AURORA | CO | 80045-7335 | ADAMS | USA | R44CA232963 | DT-EGF Toxic Fusion Protein for the Treatment of Bladder Cancer | 000 | 3 | NIH | 4/19/2023 | $999,955 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2020 | AURORA ONCOLOGY, INC. | 12635 E MONTVIEW BLVD STE 100M | AURORA | CO | 80045-7336 | ADAMS | USA | R44CA232963 | DT-EGF Toxic Fusion Protein for the Treatment of Bladder Cancer | 000 | 2 | NIH | 8/23/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2020 | AURORA ONCOLOGY, INC. | 12635 E MONTVIEW BLVD STE 100M | AURORA | CO | 80045-7336 | ADAMS | USA | R44CA232963 | DT-EGF Toxic Fusion Protein for the Treatment of Bladder Cancer | 000 | 2 | NIH | 8/30/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,000,745 ) |
| | 2020 | 2020 | AURORA ONCOLOGY, INC. | 12635 E MONTVIEW BLVD STE 100M | AURORA | CO | 80045-7336 | ADAMS | USA | R44CA232963 | DT-EGF Toxic Fusion Protein for the Treatment of Bladder Cancer | 000 | 2 | NIH | 9/10/2020 | $1,000,745 |
| | 2020 | 2017 | AURORA ONCOLOGY, INC. | 12635 E MONTVIEW BLVD STE 100M | AURORA | CO | 80045-7336 | ADAMS | USA | R43AI131870 | Development of Antimicrobial Peptides to Target Gram-negative Pathogens | 000 | 1 | NIH | 12/27/2019 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $0 ) |
| | 2019 | 2018 | AURORA ONCOLOGY, INC. | 12635 E MONTVIEW BLVD STE 100M | AURORA | CO | 80045-7336 | ADAMS | USA | R44CA232963 | DT-EGF Toxic Fusion Protein for the Treatment of Bladder Cancer | 000 | 1 | NIH | 11/20/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $299,937 ) |
| | 2018 | 2018 | AURORA ONCOLOGY, INC. | 12635 E MONTVIEW BLVD STE 100M | AURORA | CO | 80045-7336 | ADAMS | USA | R44CA232963 | DT-EGF Toxic Fusion Protein for the Treatment of Bladder Cancer | 000 | 1 | NIH | 8/28/2018 | $299,937 |
|
| Issue Date FY: 2017 ( Subtotal = $299,971 ) |
| | 2017 | 2017 | AURORA ONCOLOGY, INC. | 12635 E MONTVIEW BLVD STE 100M | AURORA | CO | 80045-7336 | ADAMS | USA | R43AI131870 | Development of Antimicrobial Peptides to Target Gram-negative Pathogens | 000 | 1 | NIH | 8/16/2017 | $299,971 |
|
| Issue Date FY: 2012 ( Subtotal = $149,040 ) |
| | 2012 | 2012 | AURORA ONCOLOGY INC | 2124 PINEDROP LANE | GOLDEN | CO | 80401 | JEFFERSON | USA | R43CA174011 | DT-EGF TOXIC FUSION PROTEIN FOR TREATMENT OF BLADDER CANCER | 000 | 1 | NIH | 9/26/2012 | $149,040 |
|
|
